U.K. stocks still seeing investor outflows in Jan .. GSK should help buck that trend, excellent outlook and kitchen sinked the zantac issue so all to play for here |
Think its for those to lazy to look at rns |
Share buyback should lend good support and will be buying stock at a low valuation, so the sooner they start the better |
Share price is range bound, gone nowhere for decades. |
Trader
Why do you repeat that which is already in the public domain? |
GSK delivers strong 2024 performance with further improvement to long-term growth outlook
Strong sales and Core EPS growth reflecting accelerating momentum in Specialty Medicines offsetting lower Vaccine sales
•
Total 2024 sales £31.4 billion +3% AER; +7% CER
•
Specialty Medicines sales +19%. HIV sales +13%. Oncology +98%. Respiratory/Immunology and Other +13%
•
Vaccines sales -4%. Shingrix +1% and Arexvy -51%
•
General Medicines sales +6%. Trelegy +27%
•
Total operating profit -33% and Total EPS -40% largely driven by £1.8 billion ($2.3 billion) charge relating to settlement of Zantac litigation
•
Core operating profit +11% (with further positive impact of +2% ex COVID) and Core EPS +10% (with further positive impact of +2% ex COVID) reflecting strong Specialty Medicines performance and disciplined increased investment in progressing the R&D portfolio
•
Cash generated from operations in the year of £8 billion with Free cash flow of £3 billion |
It's the pipeline-for the first time in years GSK has one. |
No thanks. Keep it British |
Now's the time if there are any predators looking for a cheap acquisition. |
Errr funny enough market doesn't seem to agree with you - I will take their opinion |
#Gary Cook, this could indeed be the set of catalysts that reverse the share price trend for us longer term, 2000 pence for FY-2025 sounds a mile off today but these things can happen.. :o)
Sales and profit growth
Growth in dividends
GBP 2BN of share buybacks over 18 months |
Bit of a relief for me after the clanger of VOD yesterday |
Bring it on 1,500p,1,600p,1,700p,and 1,800p.Could we see 2000p by year end. Possible ! |
Which is good for a pharma and its rising |
Big thumbs up from the market, mind the gap.. :o)
Worth waiting for, but it was painful watching the slide from 1800-1300 over 2024.. |
Well, happy enough with those results and glad I added quite a few of this oversold share. The increase in dividend is nice, however at current share price represents a yield of 'only' 4%. |
GSK delivers strong 2024 performance with further improvement to long-term growth outlook
Strong sales and Core EPS growth reflecting accelerating momentum in Specialty Medicines offsetting lower Vaccine sales
•
Total 2024 sales £31.4 billion +3% AER; +7% CER
•
Specialty Medicines sales +19%. HIV sales +13%. Oncology +98%. Respiratory/Immunology and Other +13%
•
Vaccines sales -4%. Shingrix +1% and Arexvy -51%
•
General Medicines sales +6%. Trelegy +27%
•
Total operating profit -33% and Total EPS -40% largely driven by £1.8 billion ($2.3 billion) charge relating to settlement of Zantac litigation
•
Core operating profit +11% (with further positive impact of +2% ex COVID) and Core EPS +10% (with further positive impact of +2% ex COVID) reflecting strong Specialty Medicines performance and disciplined increased investment in progressing the R&D portfolio
•
Cash generated from operations in the year of £8 billion with Free cash flow of £3 billion |
Nobody who has been watching GSK should be surprised at the beat. Too many brokers myopic obsession with current vaccine sales have made this stock a bargain |
GSK: GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV and oncology portfolio offset weakness in its vaccines division. |
Won't be adding on the back of latest update heartening though it is
But instills a bit more confidence in the position I do hold.
Onwards and upwards (Trump pronouncements not withstanding) |
Will the Market like the Results. Should do with the 6.67% dividend increase, and the Buyback. But Mr Market can be unpredictable ! |
The Zantac settlement is ugly, no doubts about that, but it is now costed and accounted for, todays results could/should help reverse the trend which sent us down from 1800 to 1300, and yesterdays mark down for starters, supported by the growing dividend and coming buybacks over 18 months..
See how the market likes it.. :o) |
Register for real-time alerts, custom portfolio, and market movers
Hot Features
Premium
